» AdjuTec CEO aims for better and safer antibiotics
» Alzinova's CEO summarizes 2023 and looks ahead
» BioInvent reaches research milestone in collaboration with Exelixis
» Abliva receives FDA Fast Track status
» PHI links up with two regenerative medicine networks
Read BioStock's weekly newsletter for v.36 here.
Morning news
WntResearch informs about participation in TO6. Read more.
Scandion Oncology adds Lars Damstrup as the new medical director. Read more.
Alexander Dahlquist new CFO at PharmNovo. Read more.
Egetis announces participation in medical conferences. Read more.
Bioretec signs a distribution agreement with Spartan Medical. Read more.
Cessatech agree with EMA current plan for CT002. Read more.
Beactica Therapeutics strengthens his team. Read more.
Salipro Biotech in research collaboration with Sumitomo Pharma. Read more.
Multi4 Medical winner in China Innovation & Entrepreneurship International Competition. Read more.
Analyst Group publishes analysis article on PolarCool. Read more.
Don't miss the BioStock Investor Pitch tomorrow, September 13th at 9.15:XNUMX with Invent Medic and CEO Anna LindstromFollow the presentation via the banner below!
Reports
Capital Market Days
Share transactions
Company presentations
News since Monday lunch
Arcede Pharma has announced the outcome of the rights issue. Read more.
QuiaPEG has announced the outcome for TO10. Read more.
New CEO in OncoZenge. Read more.
Last day including the right to subscribe for units in PolarCool Today is September 12th. Read more.
Phase Holographic has moved its annual general meeting. Read more.
Pharmiva has postponed its Q3 report. Read more.
AstraZeneca has announced new results with Phasenra. Read more.
Xspray Pharma has entered into a settlement agreement with BMS current Dasynoc. Read more.
Dental has signed a loan agreement with Danske Bank. Read more.
Observe Medical has purchased assets and raised new capital. Read more here and here.
S2Medical has appealed the district court's decision. Read more.
Medivir Partner Tango Therapeutics has received the green light for a phase I/II study with TNG348. Read more.
Three people from ProstaLunds management team has resigned. Read moreThe company's Schelin Catheter has premiered in France. Read more.
Nightingale Health has updated its strategy. Read more.
The period of use for Coala-Life Groups TO 1 has been initiated. Read more.
Annex will present at the Redeye Investor Forum. Read more.
This morning's price development
Winner: Xspray Pharma 19,1%, Cessatech 17,1%, Observe Medical 13,3%, Coegin 13,1%, Bioretec 11,1%
Förlorare: Prostalund -18,9%, Spermosens -11,9%, Double Bond Pharma -11,6%, Arcede Pharma -8,6%, Klaria -8,5%
Index: OMSX30 2189 +0,2%, Healthcare +0,8%
More from BioStock
» SynAct Pharma's CEO comments on study data from EXPAND
» Toleranzia's CEO: "Several large companies are following us"
» WntResearch provides update ahead of TO6 release
» Dicot doses first phase I participants
» Annexin CEO: “By far our biggest success in a long time”